|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0332849,
umls-concept:C0439858,
umls-concept:C0444956,
umls-concept:C0814225,
umls-concept:C0936012,
umls-concept:C1515021,
umls-concept:C1979927,
umls-concept:C2698830
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2000-1-11
|
|
pubmed:abstractText |
The clinical advantage of high-dose therapy (HDT) over standard treatment for multiple myeloma (MM) patients has been recently assessed. Which patient subgroups benefit most from this approach is unclear.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:ArgentinoCC,
pubmed-author:BoccadoroMM,
pubmed-author:CalleaVV,
pubmed-author:DominiettoAA,
pubmed-author:GianniA MAM,
pubmed-author:LautaV MVM,
pubmed-author:MarmontFF,
pubmed-author:MolicaSS,
pubmed-author:MustoPP,
pubmed-author:PalumboAA,
pubmed-author:PileriAA,
pubmed-author:TarellaCC,
pubmed-author:TrioloSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
905-10
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10509038-Antineoplastic Agents,
pubmed-meshheading:10509038-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10509038-Cell Count,
pubmed-meshheading:10509038-Disease-Free Survival,
pubmed-meshheading:10509038-Dose-Response Relationship, Drug,
pubmed-meshheading:10509038-Follow-Up Studies,
pubmed-meshheading:10509038-Humans,
pubmed-meshheading:10509038-Longitudinal Studies,
pubmed-meshheading:10509038-Middle Aged,
pubmed-meshheading:10509038-Multiple Myeloma,
pubmed-meshheading:10509038-Plasma Cells,
pubmed-meshheading:10509038-Severity of Illness Index,
pubmed-meshheading:10509038-Survival Rate,
pubmed-meshheading:10509038-Treatment Outcome,
pubmed-meshheading:10509038-beta 2-Microglobulin
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
|
|
pubmed:affiliation |
Divisione Universitaria di Ematologia, Azienda Ospedaliera S. Giovanni Battista di Torino, via Genova 3, 10126 Turin, Italy. mario.boccadoro@unito
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
